Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (NCT05261399)
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
🩺 Plain-English Summary (8th-Grade Level)
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Who can join: Review the eligibility criteria below.
Location: Research Site — Orlando, Florida
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (214 Sites)
Showing the first 25 of 214 sites.
- Research Site — Orlando, Florida
- Research Site — Honolulu, Hawaii
- Research Site — New Brunswick, New Jersey
- Research Site — New York, New York
- Research Site — Nashville, Tennessee
- Research Site — Buenos Aires,
- Research Site — CABA,
- Research Site — Florida,
- Research Site — La Rioja,
- Research Site — Rosario,
- Research Site — Rosario,
- Research Site — San Miguel de Tucumán,
- Research Site — Viedma,
- Research Site — Fremantle,
- Research Site — Southport,
- Research Site — Waratah NSW,
- Research Site — Westmead,
- Research Site — Brussels,
- Research Site — Ghent,
- Research Site — Roeselare,
- Research Site — Belo Horizonte,
- Research Site — Cachoeiro de Itapemirim,
- Research Site — Ijuí,
- Research Site — Porto Alegre,
- Research Site — Porto Alegre,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib — La Jolla, California
- Savolitinib vs. Sunitinib in MET-driven PRCC. — La Jolla, California
- Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer — St Louis, Missouri
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC — Huntsville, Alabama
- Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy — Fullerton, California
Explore by condition: All Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.